DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Andrographolide is an investigational drug.
There have been 7 clinical trials for Andrographolide. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2016.
The most common disease conditions in clinical trials are Multiple Sclerosis, Bronchitis, and Acute Disease. The leading clinical trial sponsors are Jiangxi Qingfeng Pharmaceutical Co. Ltd., University of Chile, and Universidad Austral de Chile.
There are six US patents protecting this investigational drug and thirty-three international patents.
Recent Clinical Trials for Andrographolide
|HMPL004-6599 Phase I Dose-escalating Study||Hutchison Medipharma Limited||Phase 1|
|HMPL004-6599 Phase I Dose-escalating Study||Nestlé||Phase 1|
|HMPL004-6599 Phase I Dose-escalating Study||Nutrition Science Partners Limited||Phase 1|
Top disease conditions for Andrographolide
Top clinical trial sponsors for Andrographolide
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Andrographolide||Start Trial||Terpene derivative-based PAR1 inhibitor, preparation method thereof, and use in treatment of thrombotic diseases||SHANDONG UNIVERSITY (Jinan, CN)||Start Trial|
|Andrographolide||Start Trial||Anticancer compounds: process for their preparation and pharmaceutical compositions containing them||Dr. Reddy's Research Foundation (Hyderabad, IN)||Start Trial|
|Andrographolide||Start Trial||Compounds having anticancer activity : process for their preparation and pharmaceutical compositions containing them||Dr. Reddy's Laboratories Limited (Andhra Pradesh, IN)||Start Trial|
|Andrographolide||Start Trial||Composition of labdane diterpenes extracted from andrographis paniculata, useful for the treatment of autoimmune diseases, and alzheimer disease by activation for PPR-gamma receptors||Herbal Powers Corporation (Bradenton, FL)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Andrographolide||World Intellectual Property Organization (WIPO)||2017107262||2035-12-22||Start Trial|
|Andrographolide||World Intellectual Property Organization (WIPO)||0185710||1989-12-31||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|